Key facts
- This page summarizes Gary W. Pace's Form 4 filing for Pacira BioSciences, Inc. (PCRX).
- 2 reported transactions and 1 derivative row are listed below.
- Accepted by SEC: 16 Jun 2023, 17:36.
Gary W. Pace - 14 Jun 2023 Form 4 Insider Report for Pacira BioSciences, Inc. (PCRX)
- Reporting relationship
- Director
- Issuer ticker
- PCRX
- Reported as of
- 14 Jun 2023
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 16 Jun 2023, 17:36:14 UTC
- Prior SEC filing
- 15 May 2023
- Next SEC filing
- 20 Jun 2023
- Source filing
- View source filing
- Reporting owner signature
- /s/ Kristen Williams, Attorney-in-Fact
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Gary W. Pace filed Form 4 for Pacira BioSciences, Inc. (PCRX) on 16 Jun 2023.
Change
- Previous filing in this sequence was filed on 15 May 2023.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
PCRX
transaction
Common Stock
Award
- Transaction value
- $0
- Shares
- +1,775
- Change %
- +1.3%
- Price
- $0.000000
- Shares after
- 141,450
- Date
- 14 Jun 2023
- Ownership
- Direct
- Footnotes
- F1
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
PCRX
transaction
Derivative
Stock Option (Right to Buy)
Award
- Transaction value
- $0
- Shares
- +12,925
- Change %
- Price
- $0.000000
- Shares after
- 12,925
- Date
- 14 Jun 2023
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 12,925
- Exercise price
- $38.74
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 1 footnote
Footnote F1
Represents restricted stock units that vest on June 3, 2024, provided that the reporting person remains in continuous service with the issuer through the vesting date. Each restricted stock unit represents the contingent right to receive one share of the issuer's common stock.